This is the first report of marked improvement of oral intake by third-line nivolumab monotherapy in a gastric cancer patient with insufficient oral intake and European Cooperative Oncology Group performance status 2. We should consider immune checkpoint inhibitors for microsatellite instability-high gastric cancer, regardless of the patient's general condition.